Innate Pharma S.A. IPHYF

Company Overview

Innate Pharma S.A. is a French biotechnology company focused on developing immunotherapies for cancer and other serious diseases. The company operates within the biotechnology and biopharmaceutical industries, with a strategic emphasis on innate immunity and the development of antibody-based therapies that target natural killer (NK) cells and other components of the immune system. Innate Pharma’s core revenue drivers include research collaborations, licensing agreements, milestone payments from pharmaceutical partners, and potential future commercialization of therapeutic candidates. Its development pipeline includes monoclonal antibodies, NK cell engagers, and antibody-drug conjugates designed to improve immune-mediated tumor destruction.

The company primarily serves oncology markets, partnering with large pharmaceutical companies and research institutions to advance clinical development. Innate Pharma has developed a differentiated position through its expertise in innate immune checkpoint biology and NK cell therapeutics, areas that remain less crowded than traditional T-cell immuno-oncology. Founded in 1999 in Marseille, France, the company evolved from an academic research-driven biotechnology firm into a publicly traded clinical-stage immunotherapy company listed on Euronext Paris and Nasdaq under the ticker IPHA. Over time, it expanded through strategic alliances with global pharmaceutical companies and increased investment in translational research and proprietary technology platforms.